Cargando…

Overcoming Drug Resistance and Treating Advanced Prostate Cancer

Most of the prostate cancers (PCa) in advanced stage will progress to castration-resistant prostate cancer (CRPC). Within CRPC group, 50-70% of the patients will develop bone metastasis in axial and other regions of the skeleton. Once PCa cells spread to the bone, currently, no treatment regimens ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Semenas, Julius, Allegrucci, Cinzia, Boorjian, Stephen A, Mongan, Nigel P, Persson, Jenny Liao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474961/ https://www.ncbi.nlm.nih.gov/pubmed/22746994 http://dx.doi.org/10.2174/138945012802429615

Ejemplares similares

Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
por: Semenas, Julius, et al.
Publicado: (2013)

Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells
por: Sarwar, Martuza, et al.
Publicado: (2016)

HOXC8 regulates self-renewal, differentiation and transformation of breast cancer stem cells
por: Shah, Mansi, et al.
Publicado: (2017)

Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing
por: Bahmad, Hisham F., et al.
Publicado: (2022)

The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer
por: Mandel, Anna, et al.
Publicado: (2018)

PIP5K1α is Required for Promoting Tumor Progression in Castration-Resistant Prostate Cancer
por: Wang, Tianyan, et al.
Publicado: (2022)

Targeted inhibition of ERα signaling and PIP5K1α/Akt pathways in castration‐resistant prostate cancer
por: Semenas, Julius, et al.
Publicado: (2020)

Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances
por: Movassaghi, Miyad, et al.
Publicado: (2021)

Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer
por: Harris, Anna E., et al.
Publicado: (2022)

Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer
por: Lin, Jian-Zhong, et al.
Publicado: (2017)

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer
por: Biersack, Bernhard, et al.
Publicado: (2022)

Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer
por: Tinzl, Martina, et al.
Publicado: (2013)

Correction: Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer
por: Tinzl, Martina, et al.
Publicado: (2018)

A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer
por: Sooi, Kenneth, et al.
Publicado: (2023)

Overcoming prostate cancer drug resistance with a novel organosilicon small molecule
por: Zhao, Rui, et al.
Publicado: (2021)

FcγRIIIa receptor interacts with androgen receptor and PIP5K1α to promote growth and metastasis of prostate cancer
por: Larsson, Per Flodbring, et al.
Publicado: (2022)

Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system
por: Sun, Xiangyu, et al.
Publicado: (2023)

The functional interlink between AR and MMP9/VEGF signaling axis is mediated through PIP5K1α/pAKT in prostate cancer
por: Larsson, Per, et al.
Publicado: (2019)

Combating and overcoming drug resistance in cancer
por: Price, Douglas K.
Publicado: (2014)

Nanomedicines for Overcoming Cancer Drug Resistance
por: Hu, Tingting, et al.
Publicado: (2022)

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
por: Vander Ark, Alexandra, et al.
Publicado: (2018)

Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer
por: Mulvey, Arthur, et al.
Publicado: (2022)

The dog as an animal model for bladder and urethral urothelial carcinoma: Comparative epidemiology and histology
por: de Brot, Simone, et al.
Publicado: (2018)

Selective degradation of AR-V7 to overcome castration resistance of prostate cancer
por: Liu, Yuan, et al.
Publicado: (2021)

Targeted chemotherapy overcomes drug resistance in melanoma
por: Yue, Jingyin, et al.
Publicado: (2020)

Overcoming docetaxel resistance in prostate cancer: a perspective review
por: Hwang, Clara
Publicado: (2012)

Erratum: Overcoming immune resistance with radiation therapy in prostate cancer
Publicado: (2023)

A Novel Radiographic Pattern Related to Poor Prognosis in Patients with Prostate Cancer with Metastatic Spinal Cord Compression
por: Wänman, Johan, et al.
Publicado: (2022)

Editorial: Adopting drug repurposing to overcome drug resistance in cancer
por: Shankar, Eswar, et al.
Publicado: (2023)

A Case of Identity: HOX Genes in Normal and Cancer Stem Cells
por: Smith, Jessica, et al.
Publicado: (2019)

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
por: Wang, Quan, et al.
Publicado: (2018)

Challenges for Triple Negative Breast Cancer Treatment: Defeating Heterogeneity and Cancer Stemness
por: Mahmoud, Rinad, et al.
Publicado: (2022)

Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance
por: Maity, Swastika, et al.
Publicado: (2020)

Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening
por: Hongo, Hiroshi, et al.
Publicado: (2021)

The new concepts on overcoming drug resistance in lung cancer
por: Zhang, Weisan, et al.
Publicado: (2014)

Optimization Of Cancer Treatment Through Overcoming Drug Resistance
por: Elshimali, Yahya I., et al.
Publicado: (2018)

Overcoming Cancer Drug Resistance Utilizing PROTAC Technology
por: Burke, Matthew R., et al.
Publicado: (2022)

Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing
por: El Zarif, Talal, et al.
Publicado: (2022)

Targeting epigenetic regulators to overcome drug resistance in cancers
por: Wang, Nan, et al.
Publicado: (2023)

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase
por: Lin, Hui-Ming, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nknvbtmhed408kb8hekcj3nbk6